Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer
Metrics: PDF 1245 views | HTML 1943 views | ?
Tao Wang1,2, Xiangyun Qu1, Jiajia Jiang3, Peng Gao1, Dingding Zhao1, Xueqi Lian3 and Xiaohua Li3,4
1Key Laboratory of PreMed Precision Medicine, Soochow University, Suzhou, 215121, China
2Jiangsu Provincial Key Laboratory of Molecular Biology and Translational Medicine of Malignant Tumor, Suzhou, 215123, China
3Affiliated AoYang Hospital of Jiangsu University, Zhangjiagang, Suzhou, 215600, China
4Nanjing Medical University, Nanjing, 211166, China
Xiaohua Li, email: email@example.com
Keywords: prostate cancer antigen 3, prostate-specific antigen, prostate cancer, diagnostic signature, cell-free
Received: November 01, 2016 Accepted: March 31, 2017 Published: April 20, 2017
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively. Additionally, the AUROC for serum tPSA was 0.674 with a low specificity of 12.07%. Finally, the algorithm of PCA3 RNA versus PSA RNA was evaluated and corroborated as CaP biomarker by conducting a multicentric clinical trial. This study not only validated the developed technique of qRT-PCR with TaqMan assay for examination of urinary PCA3 and PSA RNA, it also demonstrated that the score of the PCA/PSA RNA was a reliable signature for CaP diagnosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.